Stock Scorecard
Stock Summary for Aerovate Therapeutics Inc (AVTE) - $1.90 as of 9/6/2024 8:16:53 PM EST
Total Score
12 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AVTE
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AVTE
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AVTE
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AVTE
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for AVTE
Financial Details for AVTE
Company Overview |
|
|---|---|
| Ticker | AVTE |
| Company Name | Aerovate Therapeutics Inc |
| Country | USA |
| Description | Aerovate Therapeutics, Inc., a clinical-phase biopharmaceutical company, is focused on developing drugs that improve the lives of patients with rare cardiopulmonary diseases. The company is headquartered in Boston, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 6/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.90 |
| Last Day Price Updated | 9/6/2024 8:16:53 PM EST |
| Last Day Volume | 170,654 |
| Average Daily Volume | 295,670 |
| 52-Week High | 32.41 |
| 52-Week Low | 1.25 |
| Last Price to 52 Week Low | 52.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 34.82 |
| Sector PE | 80.12 |
| 5-Year Average PE | -5.76 |
| Free Cash Flow Ratio | 0.53 |
| Industry Free Cash Flow Ratio | 13.19 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 6.51 |
| Total Cash Per Share | 3.61 |
| Book Value Per Share Most Recent Quarter | 3.27 |
| Price to Book Ratio | 0.59 |
| Industry Price to Book Ratio | 6.02 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 7.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
| Total Shares Outstanding | 28,867,700 |
| Market Capitalization | 54,848,630 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -46.61% |
| Reported EPS 12 Trailing Months | -3.13 |
| Reported EPS Past Year | -1.69 |
| Reported EPS Prior Year | -2.88 |
| Net Income Twelve Trailing Months | -87,937,000 |
| Net Income Past Year | -75,521,000 |
| Net Income Prior Year | -51,511,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 104,200,000 |
| Total Cash Past Year | 122,400,000 |
| Total Cash Prior Year | 129,200,000 |
| Net Cash Position Most Recent Quarter | 104,200,000 |
| Net Cash Position Past Year | 122,400,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 2,500,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 109,456,000 |
| Total Stockholder Equity Prior Year | 126,743,000 |
| Total Stockholder Equity Most Recent Quarter | 94,398,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -74,613,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.58 |
| Free Cash Flow Past Year | -56,920,000 |
| Free Cash Flow Prior Year | -39,317,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.22 |
| MACD Signal | -0.33 |
| 20-Day Bollinger Lower Band | -9.17 |
| 20-Day Bollinger Middle Band | 9.19 |
| 20-Day Bollinger Upper Band | 27.54 |
| Beta | 1.03 |
| RSI | 38.99 |
| 50-Day SMA | 14.83 |
| 150-Day SMA | 16.39 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 9/6/2024 6:43:32 PM EST |